8-K: TScan Therapeutics Reports Q4/FY25 Results, Advances Heme Program

TScan Therapeutics announced its Q4 and full-year 2025 financial results, highlighting positive clinical data for its heme program and FDA clearance for new TCR-T candidates.

Summary

• Positive updated data from the ALLOHA Phase 1 heme trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025.
• TSC-101 was well-tolerated with no dose-limiting toxicities observed in the ALLOHA trial.
• The treatment arm of the ALLOHA trial continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52).
• 3 out of 3 (100%) TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to 1 out of 4 (25%) in the control arm.
• Enrollment in Cohort C of the Phase 1 ALLOHA trial was completed in February 2026, with patients being dosed using a commercial-ready manufacturing process.
• The FDA cleared Investigational New Drug (IND) applications for TSC-102-A01 and TSC-102-A03 in February 2026, targeting CD45 in patients with HLA types A*01:01 and A*03:01, respectively.
• The PLEXI-T trial for solid tumors was discontinued in November 2025.
• Revenue for the fourth quarter of 2025 was $2.6 million, up from $0.7 million in Q4 2024.
• Full-year 2025 revenue was $10.3 million, up from $2.8 million in full-year 2024.
• Net loss for the fourth quarter of 2025 was $23.0 million, an improvement from $35.8 million in Q4 2024.
• Net loss for the full-year 2025 was $129.8 million, compared to $127.5 million for the full-year 2024.
• Cash and cash equivalents as of December 31, 2025, were $152.4 million (excluding $5.0 million of restricted cash), projected to fund operations into the second half of 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, driven by promising clinical data in the heme program, regulatory clearances, and an extended cash runway, despite an increased full-year net loss and a program discontinuation.

Positives

• Positive updated data from the ALLOHA Phase 1 heme trial showed favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52).
• 100% (3/3) of TSC-101-treated patients who reached two-year follow-up remained relapse-free, compared to 25% (1/4) in the control arm.
• TSC-101 was well-tolerated with no dose-limiting toxicities observed.
• FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 expands the heme program, potentially allowing treatment for twice as many patients.
• Completion of enrollment in Cohort C of the Phase 1 ALLOHA trial, utilizing a commercial-ready manufacturing process, indicates manufacturing readiness.
• Revenue significantly increased for Q4 2025 to $2.6 million from $0.7 million in Q4 2024, and for full-year 2025 to $10.3 million from $2.8 million in full-year 2024.
• Net loss for Q4 2025 decreased to $23.0 million from $35.8 million in Q4 2024.
• Existing cash and cash equivalents of $152.4 million are sufficient to fund current operating plans into the second half of 2027, providing a solid financial runway.

Negatives

• The PLEXI-T trial for the solid tumor program was discontinued in November 2025.
• Full-year 2025 net loss increased to $129.8 million from $127.5 million in full-year 2024.
• Total stockholders' equity decreased significantly from $240,970 thousand as of December 31, 2024, to $123,123 thousand as of December 31, 2025.

Risks

• The beneficial characteristics, safety, efficacy, therapeutic effects, and potential advantages of TScan's TCR-T therapy product candidates may not be realized.
• TScan's expectations regarding its preclinical studies being predictive of clinical trial results may not hold true.
• Approved INDs may not be indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer.
• The timing of the launch, initiation, progress, expected results, and announcements of TScan's preclinical studies, clinical trials, and its research and development programs are subject to change.
• TScan's ability to enroll patients for its clinical trials within its expected timeline may be challenged.
• TScan's plans relating to developing and commercializing its TCR-T therapy product candidates, if approved, including sales strategy, may not be successful.
• Estimates of the size of the addressable market for TScan's TCR-T therapy product candidates may be inaccurate.
• TScan's manufacturing capabilities and the scalable nature of its manufacturing process may encounter difficulties.
• TScan's estimates regarding expenses, future milestone payments and revenue, capital requirements, and needs for additional financing may prove incorrect.
• TScan faces significant competition in the biotechnology and cell therapy sectors.
• TScan's anticipated growth strategies may not be achieved.
• TScan's ability to attract or retain key personnel is crucial and not guaranteed.
• TScan's ability to establish and maintain development partnerships and collaborations is essential for progress.
• TScan's expectations regarding federal, state, and foreign regulatory requirements may change or become more stringent.
• TScan's ability to obtain and maintain intellectual property protection for its proprietary platform technology and product candidates is critical.
• The sufficiency of TScan's existing capital resources to fund its future operating expenses and capital expenditure requirements is an ongoing concern.

Future Outlook

TScan Therapeutics anticipates continued momentum in its hematologic malignancies program, with plans to share initial data from Cohort C of the ALLOHA study and initiate its first Phase 3 trial in the second quarter of 2026. Updated Cohort C data are expected in the second half of 2026. A Phase 1 study for the newly cleared TSC-102-A01 and TSC-102-A03 candidates is slated for initiation in the second half of 2026. Additionally, the company expects to share preclinical proof-of-concept data for its autoimmunity program in the second half of 2026 and is actively developing methods for in vivo engineering to treat solid tumors.

Management Comments

• "The regulatory and operational progress we have made over the last several months related to our heme program is exciting. We expect the momentum to continue into the second quarter when we plan to share the initial data from patients enrolled into Cohort C in the ALLOHA study as well as initiate TScan's first Phase 3 trial."
• "The data we presented at ASH in December 2025 continue to support our decision to focus the Company's efforts on development of therapeutics for patients with heme malignancies."
• "Additionally, the recent FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 will allow us to bring our TCR-T therapies to twice as many patients who currently have limited options in the post-transplant setting."

Industry Context

StockSavvy.ai notes that TScan Therapeutics operates in the highly competitive and innovative field of T cell receptor (TCR)-engineered T cell (TCR-T) therapies, a segment of immuno-oncology. The company's strategic focus on hematologic malignancies, particularly preventing relapse post-allogeneic hematopoietic cell transplantation (HCT), addresses a critical unmet medical need. The discontinuation of the solid tumor PLEXI-T trial, while a setback, reflects a common biotech strategy to prioritize resources towards programs demonstrating more promising early clinical data. The expansion of the heme program with new FDA IND clearances positions TScan to potentially broaden its addressable patient population within this specialized niche, aligning with broader industry trends of developing highly targeted cell therapies.

Comparison to Industry Standards

• The reported relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) for TSC-101 in the ALLOHA Phase 1 trial, while from early-stage data, show promising trends that could differentiate it from historical outcomes for high-risk heme malignancy patients post-HCT, where relapse rates are often high. For example, typical relapse rates for acute myeloid leukemia (AML) post-HCT can range from 30-70% depending on risk factors.
• The 100% relapse-free rate at two-year follow-up for 3 out of 3 treated patients is a strong early signal, though from a very small sample size. This would need to be validated in larger, later-stage trials to compare definitively against established therapies or other emerging TCR-T platforms from competitors like Adaptimmune or Kite Pharma (a Gilead company), which have advanced TCR-T or CAR-T therapies in various cancer indications.
• The FDA clearance of two new INDs (TSC-102-A01 and TSC-102-A03) demonstrates regulatory progress, aligning with the pace of development seen in other clinical-stage biotechnology companies advancing novel cell therapies, such as those from bluebird bio or Allogene Therapeutics, which also navigate complex regulatory pathways for their cell therapy candidates.

Stakeholder Impact

• Shareholders: Positive clinical data and an extended cash runway could increase investor confidence, while the increased full-year net loss and program discontinuation might temper enthusiasm.
• Patients: Expansion of the heme program with new INDs and progression to a pivotal trial offers hope for new treatment options for patients with hematologic malignancies, especially those with limited post-transplant options.
• Employees: Strategic prioritization of the heme program and discontinuation of the solid tumor program may lead to reallocation of resources and potential shifts in team focus.
• Partners (Amgen): Continued collaboration revenue indicates ongoing research activities, suggesting a stable partnership.

Next Steps

• Share early clinical data on patients treated in Cohort C of the ALLOHA study in the second quarter of 2026.
• Launch pivotal trial for TSC-101 in the second quarter of 2026.
• Share updated data on patients treated in Cohort C of the ALLOHA study in the second half of 2026.
• Initiate Phase 1 study of TSC-102-A01 and TSC-102-A03 in the second half of 2026.
• Anticipate sharing preclinical proof-of-concept data for its therapeutic approach in the autoimmunity program in the second half of 2026.

Key Dates

Recommendation

The positive clinical data and regulatory clearances for the heme program are significant advancements, extending the cash runway into H2 2027. However, the discontinuation of the solid tumor program and the increased full-year net loss indicate ongoing challenges and the high-risk nature of biotech development. While there's clear progress, the company remains in a clinical stage with substantial future capital needs for pivotal trials and commercialization. A 'hold' recommendation reflects the promising but early-stage nature of the core assets, balanced against the inherent risks and the need for further validation in larger trials.

Keywords

TScan Therapeutics, TCRX, TCR-T therapy, hematologic malignancies, ALLOHA trial, TSC-101, TSC-102-A01, TSC-102-A03, FDA clearance, IND, clinical trial, biotechnology, cancer treatment, financial results, Q4 2025, full year 2025, cash position, R&D, net loss, corporate updates, autoimmune disorders, solid tumors